Startside532523 • BOM
add
Biocon Ltd
Forrige sluttkurs
390,35 ₹
Dagsintervall
390,30 ₹ - 396,85 ₹
Årsintervall
290,80 ₹ - 424,95 ₹
Markedsverdi
474,09 mrd. INR
Gjennomsnittlig volum
121,51k
P/E-tall
81,58
Utbytte
0,13 %
Hovedbørs
NSE
I nyhetene
Økonomi
Resultatregnskap
Omsetning
Nettoomsetning
| (INR) | des. 2025info | Endring år til år |
|---|---|---|
Omsetning | 41,73 mrd. | 9,20 % |
Driftskostnader | 25,16 mrd. | 17,78 % |
Nettoomsetning | 1,44 mrd. | 472,91 % |
Netto resultatmargin | 3,45 | 422,73 % |
Fortjeneste per aksje | 2,74 | 1 986,89 % |
EBITDA | 7,13 mrd. | 0,91 % |
Faktisk avgiftssats | 23,60 % | — |
Balanseregnskap
Totale aktiva
Totale passiva
| (INR) | des. 2025info | Endring år til år |
|---|---|---|
Kontant / kortsiktige inv. | 61,04 mrd. | 130,29 % |
Totale aktiva | — | — |
Totale passiva | — | — |
Total egenkapital | 330,55 mrd. | — |
Utestående aksjer | 1,33 mrd. | — |
P/B-forhold | 1,88 | — |
Avkastning på aktiva | — | — |
Avkastning på kapital | 1,60 % | — |
Kontantstrøm
Netto kontantstrøm
| (INR) | des. 2025info | Endring år til år |
|---|---|---|
Nettoomsetning | 1,44 mrd. | 472,91 % |
Kontantstrøm fra drift | — | — |
Kontanter fra investering | — | — |
Kontanter fra finansiering | — | — |
Netto kontantstrøm | — | — |
Fri kontantstrøm | — | — |
Om
Biocon Limited is an Indian biopharmaceutical company based in Bengaluru, with U.S. headquarters in Bridgewater, New Jersey. The company was founded by Kiran Mazumdar-Shaw in 1978. The company manufactures generic active pharmaceutical ingredients that are sold in approximately 120 countries, including the United States and Europe. It also manufactures novel biologics as well as biosimilar insulins and antibodies, which are sold in India as branded formulations. Biocon's biosimilar products are also sold in both bulk and formulation forms in several emerging markets.
Biocon's formulations for the Indian market include metabolics, oncology, immunotherapy, and nephrology products. Some of Biocon's key brands in India include INSUGEN, BASALOG, BIOMAb EGFR, BLISTO, CANMAb, Evertor, TACROGRAF, ALZUMAb and KRABEVA.
Syngene International Limited is a publicly listed subsidiary of Biocon, operating in the contract research and development organization. Wikipedia
Administrerende direktør
Grunnlagt
29. nov. 1978
Hovedkvarter
Nettsted
Ansatte
16 420